Perindopril and hydrochlorthiazide effects on endothelium-dependent vasodilatation and angiotensin-converting enzyme activity in patients with mild to moderate arterial hypertension

Aim. During 12-week perindopril (PR) and hypothiazide (HT) therapy, to study its antihypertensive efficacy, as well as its influence on endothelial function (EF) and angiotensin-converting enzyme (ACE) serum activity, in patents with essential arterial hypertension (EAH).
Material and methods. The study included 20 males (mean age 48.8±8.4 years) with mild to moderate AH. Antihypertensive efficacy was assessed during office BP measurement (Korotkoff method) and 24-hour blood pressure monitoring (BPM). EF was assessed by endothelium-dependent vasodilatation (EDVD) during reactive hyperemia test (RHT).
Results. According to office BP measurements, target BP level (<140/90 mm Hg) was achieved in 75% patients on PR monotherapy, and 65% on HT monotherapy. According to 24-hour BPM, PR influenced BP levels more beneficially than HT. During PR and HT monotherapy, antihypertensive effect was more pronounced in patients with moderate AH (p=0.06). PR monotherapy caused some EDVD increase in patients with moderate AH (by 10%; NS), but did not affect EDVD in individuals with mild AH. HT treatment substantially increased EDVD in patients with mild AH (by 24%, from 7.13 to 9.18) and even more in participants with moderate AH (by 54%, from 6.52 to 10.02). PR therapy significantly reduced ACE activity, increased at baseline, to 28.1 nmol/min•ml (-43%, p<0.01). In patients with initially low ACE activity, it remained at the same level (reduction to 21.16 nmol/min•ml, NS). HT treatment did not affect this parameter in participants with low or high initial ACE activity.
Conclusion. PR and HT antihypertensive effects were associated with EDVD correction. PR and HT antihypertensive efficacy depended on baseline ACE activity. Both drugs could be used for BP correction in individuals with low ACE activity; for patients with initially high ACE activity, PR is more effective.

1. Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension 1983; 5: 881-6.

2. Santoso T. Improvement of endothelial dysfunction as a surrogate endpoint in the treatment of hypertension. Curr Hypertens Rep 2000; 2(3): 227-9.

3. О.А.Гомазков. Пептиды в кардиологии. Москва «Материк альфа» 2000.

4. On YK, Kim CH, Oh BH, et al. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002; 25(3): 365-71.

5. Tezcan H, Yavuz D, Toprak A, et al. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003; 4(2): 119-23.

6. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60(4): 191-6.

7. Соболева Г.Н., Балахонова Т.В., Рогоза А.Н. и др. Вазопротекция при гипертонической болезни: влияние рамиприла на функциональное состояние плечевой артерии. Кардиология 1998; 6: 44-7.

8. Бувальцев В.И., Спасская М.Б., Небиеридзе Д.В. и др. Фармакологическая модуляция синтеза NO у больных с артериальной гипертонией и эндотелиальной дисфункцией. Клин мед 2003; 81(7): 51-5.

9. Berkels R, Roesen R, Bartels H, et al. Nisoldipine increases the bioavailabity of endothelial NO. Naunyn Schmiedebergs Arch. Pharmacol 2000; 364(2): 110-6.

10. Luscher TF, Barton M. Biology of endothelium. Clin Cardiol 1997; 20(11 Suppl 2): 3-10.

11. 11. Ding Y, Vaziri ND. Nifedipine and Diltiazem but Not Verapamil Up-Regulate Endothelial Nitric-Oxide Synthase Expression. J Pharmacol Exp Ther 2000; 292: 606-9.

12. Ohlstein EN, Brooks DP, Feurstein GZ, Ruffolo RR. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blocade. Pharmacology 1997; 55(5): 244-51.

13. Muiesan ML, Salvetti M, Monteduro С, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999; 33: 575-80.

14. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscules. Am J Med 1988; 84(Suppl. IB): 10-4.

15. Junquero DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endomelium-dependent production of cyclic guanosine monophosphate by bradykinin in the canine femoral artery. Am Heart J 1991; 122(4 Pt 2): 1204-9.

16. Schini VB, Dewey J, Vanhoutte PM. Related effects of indapamide on endothelium-dependent relaxations in isolated canine femoral arteries. Am J Cardiol 1990; 65(17): H6-10.

17. Muhlen BV, Millgard J, Lind L. Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol 2001; 28(5-6): 381-5.

18. Celemajer DS, Sorensen KE, Gooch VM, et al. Non invasive detection of endothelial dysfunction in children and adult at risk of atherosclerosis. Lancet 1992; 340: 1111-5.

19. Комиссарова Н.В., Симс В-Э., Гомазков О.А. Вещество П ингибирует активность ангиотензин-конвертирующего фермента в сыворотке крови человека. Бюлл эксперим биол мед 1982; 6: 3-5.

20. Апарина Т.В., Бритов А.Н., Дилакян Е.А. и др. Значение исходного уровня активности ангиотензин-превращающего фермента у больных с метаболическим синдромом при назначении ингибиторов АПФ и агонистов имидазолиновых рецепторов. РКЖ 2001; 1: 53-7.

21. Бритов А.Н., Апарина Т.В., Небиеридзе Д.В., Гомазков О.А. Ингибиторы ангиотензин-превращающего фермента в лечении метаболического синдрома. Вопр мед хим 2000; 5: 509-10.

22. Berkenboom G. Vascular endothelium: target organ of cardiovascular pathologies. Ann Cardiol Angeiol (Paris) 1999; 48(9-10): 643-6.

23. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90(10C): 40L-8.

24. Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: what is the link? Kidney Int Suppl 2003; 84: S45-9.

25. Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16(8): 557-62.

26. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 2000; 14(2): 271-8.

27. Higashi Y, Sasaki S, Nakagawa K, et al. Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 2002; 39(5): 668-76.

28. Оганов Р.Г., Небиеридзе Д.В. Метаболические эффекты блокаторов рецепторов ангиотензина II. Кардиология 2002; 42(3): 35-9.

29. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16(2): 123-8.